Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of concurrent tislelizumab and radiotherapy in low-risk extranodal NK/T-cell lymphoma, nasal type
KCT0007602Phase 2Recruiting
- Sponsor
- BeiGene
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by BeiGene. Started May 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on KCT0007602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007602.